Trailr2-cdh17-antibody-phase1-trial Trailr2-cdh17-antibody-phase1-trial Boehringer Ingelheim advances a bi-specific therapeutic antibody to first-in-human clinical trial for patients with advanced gastrointestinal cancers
collaboration-proxygen-molecular-glue-degraders collaboration-proxygen-molecular-glue-degraders Boehringer Ingelheim collaborates with Proxygen to explore molecular glue degraders – a novel approach to fight cancer.
supplier_code_of_conduct_2020_FR_bis-2021-04-14.pdf supplier_code_of_conduct_2020_FR_bis-2021-04-14.pdf